Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3085377

CC1(C)CC=C(c2ncccc2C(N)=O)CC1.O=C(O)C(F)(F)F

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 9/20 0.39
L3MBTL1 Q9Y468 1/20 0.37
KDM4E B2RXH2 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
DDB1 Q16531 1/20 0.34
CRBN Q96SW2 1/20 0.34
TBK1 Q9UHD2 1/20 0.34
PARP1 P09874 1/20 0.34
ALDH1A1 P00352 3/20 0.33
LMNA P02545 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ALDH2 P05091 1/20 0.33
ALDH1A3 P47895 1/20 0.33
KDM5B Q9UGL1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3093923 0.92 PARP1 (0.39) CSF1RKDM4ETDP1DDB1CRBN
Trifluoroacetic Acid SCHEMBL3085379 0.86 CSF1R (0.40) CSF1RL3MBTL1TBK1ALDH1A1KDM5B
Trifluoroacetic Acid SCHEMBL3078164 0.79 L3MBTL1 (0.43) L3MBTL1KDM4ETDP1DDB1CRBN
Trifluoroacetic Acid SCHEMBL3652052 0.74 CSF1R (0.42) CSF1RTBK1
SCHEMBL3083005 0.73 KDM5B (0.37) CSF1RTBK1LMNAKDM5B
Trifluoroacetic Acid SCHEMBL18297743 0.72 CSF1R (0.40) CSF1R
SCHEMBL3089974 0.72 KDM5B (0.38) CSF1RTBK1PARP1ALDH1A1ALDH2
SCHEMBL4184064 0.71 TRPV1 (0.36) CSF1RTBK1ALDH1A1KDM5B
SCHEMBL3081410 0.71 TBK1 (0.37) CSF1RTBK1PARP1ALDH1A1ALDH2
SCHEMBL3093870 0.69 PARP1 (0.43) L3MBTL1KDM4ETDP1DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US claimed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP claimed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO claimed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US claimed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP disclosed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO disclosed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258666-A1 c-fms kinase inhibitors FLT3, FES, FER CSF1R 111/4885L3MBTL1 1454/4885KDM4E 1464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.